A very recent analysis by the Food and Drug Administration (FDA) Adverse Event Reporting System, which considered a total of 45,256 reports related to the use of SGLT-2 inhibitors, including 1714 UTI cases and 438 genital mycotic infections (GMI) cases, suggested a strong association between SGLT-2 inhibitors and UTIs/GMIs, providing real-world evidence of the potential risk of UTIs/GMIs related to SGLT-2 inhibitors [7]. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.